From the Division of Experimental Surgery, Department of Cardiovascular Surgery, German Heart Center Munich, Germany (S.A.D., M.-A.D., E.D., R.L., M.K.); Stanford Cardiovascular Institute (V.S., G.L., E.D., S.M.W.), Institute for Stem Cell and Regenerative Medicine (S.M.W.), and Division of Cardiovascular Medicine, Department of Medicine (S.M.W.), Stanford University School of Medicine, CA; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (M.-A.D., M.K.).
Circ Res. 2017 Feb 17;120(4):630-632. doi: 10.1161/CIRCRESAHA.116.310051.
A long-standing goal of cardiovascular scientists is to repair damaged hearts following myocardial infarction by overcoming the limited regenerative capacity of the adult mammalian heart. A number of new strategies are being actively investigated for generating functional cardiomyocytes or progenitor cells. The race is on for the first demonstration of durable therapeutic heart repair in human.
心血管科学家的长期目标是通过克服成年哺乳动物心脏的有限再生能力来修复心肌梗死后受损的心脏。目前正在积极研究许多新策略来生成功能性心肌细胞或祖细胞。目前正在竞相在人体中首次证明持久的治疗性心脏修复。